+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07471841

Pilot Phase 2 Study of Olutasidenib for Relapsed IDH1 Mutated Acute Myeloid Leukemia After Venetoclax Treatment

Led by Timothy Pardee · Updated on 2026-11-04

25

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating olutasidenib in patients with relapsed or refractory Acute Myeloid Leukemia AML who have an IDH1 mutation and have previously been treated with venetoclax-based regimens. This phase 2 pilot study aims to assess how well patients respond to olutasidenib after their disease progresses following prior treatment. The study focuses on patients who have not achieved complete remission with earlier therapies. Participants will receive olutasidenib orally at a dose of 150 mg twice daily for 28-day cycles. After three cycles, if complete remission is not achieved or if response is lost, azacitidine may be added for seven days each cycle at the doctors discretion. Patients showing at least partial remission after six cycles will continue treatment as described, while those without such response will enter long-term follow-up. During the study, participants will be monitored with regular assessments to evaluate their response, including remission rates and overall survival over two years. Blood counts and other hematologic parameters will be tracked, along with transfusion independence and transplant rates. Safety and treatment effects will be followed throughout participation, which may extend up to three years until study completion.

CONDITIONS

Brief Title

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Research Team

T

Timothy Pardee

A

Ahran Lee

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here